Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB091 in Relapsing Multiple Sclerosis (FUSION)
NCT05798520Phase 2Completed
- Sponsor
- Biogen
- Start
- Jul 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of biib091 in multiple sclerosis (MS), sponsored by Biogen. Started Jul 2023; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05798520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798520.